Menu
← Oncology Approval Tracker
FDA DECISION ·
Imjudo + Imfinzi + platinum-based chemotherapy
tremelimumab-actl plus durvalumab and platinum-based chemotherapy · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic NSCLC lacking sensitizing EGFR mutations and ALK genomic alterations receiving tremelimumab, durvalumab and platinum-based chemotherapy.
LAMPGEN ANALYSIS
Why it matters
This approval brings dual-checkpoint blockade with chemotherapy to a defined metastatic lung cancer population.
What research teams should watch
Confirm EGFR and ALK results and distinguish chemotherapy-related and immune-related adverse events during follow-up.
PRIMARY RECORDS